Oral targeted protein degradation has produced plenty of preclinical enthusiasm and almost no late-stage proof — which makes the parallel Phase 2b design Kymera is running with KT-621 the most consequential test of STAT6 degradation yet. Two fully powered randomized trials, BROADEN2 in roughly 200 atopic dermatitis patients and BREADTH in 264 eosinophilic asthma patients, are now enrolling simultaneously, with readouts staggered across mid- and late-2027. That sequencing is not accidental: AD data arriving first gives the program a chance to de-risk before the harder respiratory endpoint lands.
The primary endpoint in BROADEN2 is percent change from baseline in EASI score at week 16 — a well-validated measure with a clear competitive benchmark given dupilumab‘s dominance in the space. BREADTH is asking a different and more demanding question: change from baseline in pre-bronchodilator FEV1 over 12 weeks, a physiological endpoint that biologics targeting IL-4/IL-13 have moved only modestly. If an oral degrader matches or exceeds those FEV1 shifts without injection burden, the mechanistic story changes from “also-ran” to “category threat.” The Phase 1b BroADen data already showed deep STAT6 degradation in blood and lesional skin, meaningful reductions in Type 2 inflammatory biomarkers, and clinical signal across AD and comorbid allergic disease — which is precisely the biologic substrate required before committing to two expensive Phase 2b trials at once.
Two details deserve attention. Kymera expanded BROADEN2 in January 2026 to include adolescents as young as 12, a regulatory move that broadens eventual labeling ambitions but also complicates enrollment and requires demonstrating tolerability across a wider age range before a single Phase 2b data point exists. And the clean six-to-nine-month GLP toxicology package in both rat and NHP — no adverse findings at any dose — removes one of the remaining mechanistic unknowns about chronically degrading a transcription factor with broad signaling roles. That matters because STAT6 is not a peripheral enzyme; it sits at the center of IL-4 and IL-13 signaling, and chronic obliteration of it in healthy tissue has been the standing concern for this target class.
The single marker that will define this program’s trajectory: the magnitude of FEV1 improvement in BREADTH relative to the 100–150 mL gains typically reported for IL-4Rα biologics in similar eosinophilic populations. Exceed that bar with an oral agent and Kymera owns a differentiation argument no biologic can answer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
